Vectura Forays into China by Forming JV with Tianjin KingYork and Zendex Bio Strategy

By Heather Cartwright

Pharma Deals Review: Vol 2013 Issue 5 (Table of Contents)

Published: 25 May-2013

DOI: 10.3833/pdr.v2013.i5.1943     ISSN: 1756-7874

Section: Joint Venture

Fulltext:

Abstract

In order to access fast growing Asian respiratory markets, UK-based Vectura has formed a joint venture (JV) with Tianjin KingYork, a Chinese pharmaceutical company and specialist manufacturer of corticosteroid-based products, and Zendex Bio Strategy, a Hong Kong-based private equity investor...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details